Myriad Genetics to Present at the 2015 Credit Suisse Healthcare Conference
October 28 2015 - 7:05AM
Myriad Genetics, Inc. (NASDAQ:MYGN) announced today that Mark C.
Capone, president and CEO, Myriad Genetics, is scheduled to present
at the 24th Annual Credit Suisse Healthcare Conference at 5:00 pm
EST on November 11, 2015, at the Phoenician Resort in Phoenix,
Arizona.
The presentation will be available to interested parties through
a live audio webcast accessible through a link in the investor
information section of Myriad's website at www.myriad.com.
About Myriad Genetics
Myriad Genetics Inc., is a leading personalized medicine company
dedicated to being a trusted advisor transforming patient lives
worldwide with pioneering molecular diagnostics. Myriad discovers
and commercializes molecular diagnostic tests that: determine the
risk of developing disease, accurately diagnose disease, assess the
risk of disease progression, and guide treatment decisions across
six major medical specialties where molecular diagnostics can
significantly improve patient care and lower healthcare
costs. Myriad is focused on three strategic
imperatives: transitioning and expanding its hereditary cancer
testing markets, diversifying its product portfolio through the
introduction of new products and increasing the revenue
contribution from international markets. For more information
on how Myriad is making a difference, please visit the Company's
website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris
AP, myPath, myRisk, myRisk Hereditary Cancer, myChoice, myPlan,
BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, Vectra and
Prolaris are trademarks or registered trademarks of Myriad
Genetics, Inc. or its wholly owned subsidiaries in the United
States and foreign countries. MYGN-F, MYGN-G
CONTACT: Media Contact:
Ron Rogers
(801) 584-3065
rrogers@myriad.com
Investor Contact:
Scott Gleason
(801) 584-1143
sgleason@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Apr 2023 to Apr 2024